Skip to main content

Advertisement

Log in

Methylated β-cyclodextrins are able to improve the nasal absorption of salmon calcitonin

  • Laboratory Investigations
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

The absorption enhancing effect of methylated β-cyclodextrins on the nasal absorption of salmon calcitonin (sCT) was studied in rats and rabbits. The nasal absorption of sCT following administration without additives was low in both species. The absorption in rats could be largely improved by coadministration of cyclodextrins as apparent from the effect on serum calcium concentrations. Trimethyl-β-cyclodextrin (TMβCD), at a concentration of 5% (w/v), was the least potent enhancer. Randomly methylated-β-cyclodextrin (RMβCD) and dimethyl-β-cyclodextrin (DMβCD), all at a concentration of 5% (w/v), were almost equally effective in decreasing serum calcium levels, and the hypocalcemic responses were similar to those of i.v. and s.c. injected sCT. Absorption enhancement was already achieved with 1% DMβCD added to the nasal formulations. In rabbits, only the effect of DMβCD on the nasal sCT absorption was investigated. A total serum calcium decrement in 4 hours of 9.4±3.9% (mean±SD) was observed following nasal administration of 12.6 IU/kg sCT with 5% DMβCD, comparable to that of i.v.-injected sCT. In conclusion, the methylated cyclodextrins DMβCD and RMβCD are suitable absorption enhancers for nasal sCT administration, which is expected to have a clinical impact on the therapy with calcitonin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Azria M (1989) The calcitonins: physiology and pharmacology. Karger, Basel

    Google Scholar 

  2. McDermott MT, Kidd GS (1987) The role of calcitonin in the development and treatment of osteoporosis. Endocrinol Rev 8:377–390

    Google Scholar 

  3. Nagant de Deuxchaisnes C, Devogelaer JP, Haux JP, Dufour JP, Esselinckx W, Engelbeen JP, Stasse P, Hermans P, De Buisseret JP (1987) New modes of administration of salmon calcitonin in Paget's disease. Clin Orthop 217:56–71

    Google Scholar 

  4. Chien YW, Su KSE, Chang SF (1989) Nasal systemic drug delivery. Marcel Dekker, New York

    Google Scholar 

  5. Reginster JY, Franchimont P (1985) Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 3:155–157

    Google Scholar 

  6. Reginster JY, Alber A, Lecart MP, Lambelin P, Denis P, Deroisy R, Fontaine MA, Franchimont P (1987) 1-Year controlled randomised trial of prevention of early post-menopausal bone loss by intranasal calcitonin. Lancet 1481–1483

  7. Overgaard K, Angusdei D, Hansen MA, Maioli E, Christiansen C, Gennari C (1991) Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 72:344–349

    Google Scholar 

  8. Rico H, Hernandez ER, Diaz-Mediavilla J, Alvarez A, Martinez R, Espinos D (1990) Treatment of multiple myeloma with nasal spray calcitonin: a histomorphometric and biochemical study. Bone Miner 8:231–237

    Google Scholar 

  9. Rizzato G, Schiraldi G, Tosi G, Locicero S, Montemurro L, Zanni D, Sisti S (1989) Administration of salmon calcitonin nasal spray for long-term treatment of corticosteroid-induced osteoporosis. Curr Ther Res 45:761–767

    Google Scholar 

  10. Merkus FWHM, Verhoef J, Romeijn SG, Schipper NGM (1991) Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm Res 8:588–592

    Google Scholar 

  11. Schipper NGM, Verhoef JC, De Lannoy LM, Romeijn SG, Brakkee JH, Wiegant VM, Gispen WH, Merkus FWHM (1993) Nasal administration of an ACTH(4–9) peptide analogue with dimethyl-β-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics. Br J Pharmacol 110:1335–1340

    Google Scholar 

  12. Merkus FWHM, Schipper NGM, Hermens WAJJ, Romeijn SG, Verhoef J (1993) Absorption enhancers in nasal drug delivery: efficacy and safety. J Controlled Rel 24:201–208

    Google Scholar 

  13. Morimoto K, Miyazaki M, Yamaguchi H, Kakemi M (1992) Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin, an analogue and calcitonin. Proc Intern Symp Control Rel Bioact Mater 19:218–219

    Google Scholar 

  14. Hanson M, Gazdick G, Cahill J, Augustine M (1986) Intranasal delivery of the peptide salmon calcitonin. In: Davis SS, Illum L, Tomlinson E (eds) Delivery systems for peptide drugs. Plenum Press, New York, pp 233–242

    Google Scholar 

  15. Irie T, Wakamatsu K, Arima H, Aritoma H, Uekama K (1992) Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int J Pharmaceutics 84:129–139

    Google Scholar 

  16. Lee ML, Chien YW (1991) Degradation of calcitonin in buffered solution and various mucosal extracts. Pharmaceutical Res 8:S49

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schipper, N.G.M., Verhoef, J.C., Romeijn, S.G. et al. Methylated β-cyclodextrins are able to improve the nasal absorption of salmon calcitonin. Calcif Tissue Int 56, 280–282 (1995). https://doi.org/10.1007/BF00318047

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00318047

Key words

Navigation